Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study - PubMed (original) (raw)
Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study
Andrew P Boright et al. Diabetes. 2005 Apr.
Abstract
The development and progression of microvascular complications have been extensively documented in a cohort of type 1 diabetic subjects enrolled in the Diabetes Control and Complications Trial (DCCT) and followed in the Epidemiology of Diabetes Interventions and Complications (EDIC) study. We describe the association of genetic variation in the ACE gene in 1,365 DCCT/EDIC subjects with incident persistent microalbuminuria (n = 312) and severe nephropathy (n = 115). We studied three markers (rs1800764, insertion/deletion, and rs9896208) in the ACE gene that allowed us to capture genetic variation in the common haplotypes occurring at frequencies of >5% in Caucasians. Compared with the more frequent genotype (D/I) for the insertion/deletion polymorphism, in multivariate models, the I/I genotype conferred a lower risk for persistent microalbuminuria (hazard ratio [HR] 0.62 [95% CI 0.43-0.89], P = 0.009) and severe nephropathy (0.56 [0.32-0.96], P = 0.033). Variation at the two other markers, rs1800764 and rs9896208, were also associated with these renal outcomes. In addition, homozygosity for the common haplotype TIC (which corresponded to the T, insertion, and C alleles at the three markers, rs1800764, insertion/deletion, and rs9896208, respectively) versus the CDT/TIC haplotype pair was associated with lower risk for development of persistent microalbuminuria (HR 0.49 [0.32-0.75], P = 0.0009) and severe nephropathy (0.41 [0.22-0.78], P = 0.006). Our findings in the DCCT/EDIC cohort provide strong evidence that genetic variation at the ACE gene is associated with the development of nephropathy in patients with type 1 diabetes.
Figures
FIG. 1
Cumulative incidence of persistent microalbuminuria according to ACE genotype. The time was calculated from DCCT baseline to the first consecutive timed AER collection >20.8 μg/min in the DCCT or EDIC follow-up periods in individuals genotyped for three ACE polymorphisms: rs1800764, insertion/deletion, and rs9896208. For univariate analysis, see Table 2.
Similar articles
- Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study.
Al-Kateb H, Boright AP, Mirea L, Xie X, Sutradhar R, Mowjoodi A, Bharaj B, Liu M, Bucksa JM, Arends VL, Steffes MW, Cleary PA, Sun W, Lachin JM, Thorner PS, Ho M, McKnight AJ, Maxwell AP, Savage DA, Kidd KK, Kidd JR, Speed WC, Orchard TJ, Miller RG, Sun L, Bull SB, Paterson AD; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Al-Kateb H, et al. Diabetes. 2008 Jan;57(1):218-28. doi: 10.2337/db07-1059. Epub 2007 Oct 3. Diabetes. 2008. PMID: 17914031 Free PMC article. Clinical Trial. - Identification of specific angiotensin-converting enzyme variants and haplotypes that confer risk and protection against type 2 diabetic nephropathy.
Ezzidi I, Mtiraoui N, Kacem M, Chaieb M, Mahjoub T, Almawi WY. Ezzidi I, et al. Diabetes Metab Res Rev. 2009 Nov;25(8):717-24. doi: 10.1002/dmrr.1006. Diabetes Metab Res Rev. 2009. PMID: 19787680 - Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I--converting enzyme gene.
Doria A, Warram JH, Krolewski AS. Doria A, et al. Diabetes. 1994 May;43(5):690-5. doi: 10.2337/diab.43.5.690. Diabetes. 1994. PMID: 7909524 - Meta-analysis of the relationship between ACE I/D gene polymorphism and end-stage renal disease in patients with diabetic nephropathy.
Yu ZY, Chen LS, Zhang LC, Zhou TB. Yu ZY, et al. Nephrology (Carlton). 2012 Jul;17(5):480-7. doi: 10.1111/j.1440-1797.2012.01592.x. Nephrology (Carlton). 2012. PMID: 22385293 Review. - Predicting the development of diabetic nephropathy and its progression.
William J, Hogan D, Batlle D. William J, et al. Adv Chronic Kidney Dis. 2005 Apr;12(2):202-11. doi: 10.1053/j.ackd.2005.02.001. Adv Chronic Kidney Dis. 2005. PMID: 15822056 Review.
Cited by
- Nimbidiol protects from renal injury by alleviating redox imbalance in diabetic mice.
Juin SK, Pushpakumar S, Sen U. Juin SK, et al. Front Pharmacol. 2024 May 21;15:1369408. doi: 10.3389/fphar.2024.1369408. eCollection 2024. Front Pharmacol. 2024. PMID: 38835661 Free PMC article. - Diabetic Nephropathy and Gaseous Modulators.
Juin SK, Ouseph R, Gondim DD, Jala VR, Sen U. Juin SK, et al. Antioxidants (Basel). 2023 May 12;12(5):1088. doi: 10.3390/antiox12051088. Antioxidants (Basel). 2023. PMID: 37237955 Free PMC article. Review. - Urinary albumin/creatinine ratio tertiles predict risk of diabetic retinopathy progression: a natural history study from the Adolescent Cardio-Renal Intervention Trial (AdDIT) observational cohort.
Benitez-Aguirre PZ, Marcovecchio ML, Chiesa ST, Craig ME, Wong TY, Davis EA, Cotterill A, Couper JJ, Cameron FJ, Mahmud FH, Neil HAW, Jones TW, Hodgson LAB, Dalton RN, Marshall SM, Deanfield J, Dunger DB, Donaghue KC; Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT). Benitez-Aguirre PZ, et al. Diabetologia. 2022 May;65(5):872-878. doi: 10.1007/s00125-022-05661-1. Epub 2022 Feb 19. Diabetologia. 2022. PMID: 35182158 Free PMC article. - Angiotensin-Converting Enzyme Genotype-Specific Immune Response Contributes to the Susceptibility of COVID-19: A Nested Case-Control Study.
Gong P, Mei F, Li R, Wang Y, Li W, Pan K, Xu J, Liu C, Li H, Cai K, Shi W. Gong P, et al. Front Pharmacol. 2022 Jan 12;12:759587. doi: 10.3389/fphar.2021.759587. eCollection 2021. Front Pharmacol. 2022. PMID: 35095487 Free PMC article. - The Use of Genomics to Drive Kidney Disease Drug Discovery and Development.
Reilly DF, Breyer MD. Reilly DF, et al. Clin J Am Soc Nephrol. 2020 Sep 7;15(9):1342-1351. doi: 10.2215/CJN.11070919. Epub 2020 Mar 19. Clin J Am Soc Nephrol. 2020. PMID: 32193173 Free PMC article. Review.
References
- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. - PubMed
- Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia. 1983;25:496–501. - PubMed
- Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. Am J Med. 1985;78:785–794. - PubMed
- Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C, Parving HH. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care. 2003;26:1258–1264. - PubMed
- Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of type 1 diabetes: the Linkoping Diabetes Complications Study. Diabetologia. 2004;47:1266–1272. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous